Pricing wars heat up over hepatitis C drugs
February 04, 2015 at 12:13 PM EST
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.